RBC puts Allos at sector perform, $5 target

Allos Therapeutics, Inc. was reiterated at a sector perform, speculative risk, rating and a $5 price target by RBC Capital Markets analyst Michael Yee following two days of "unusual" stock outperformance. Revaluation of the company's shares seems to follow publication of an abstract expanding on positive efficacy results of its small molecule chemotherapeutic agent PDX (pralatrexate). Even though Yee believes PDX will be approved for peripheral T-cell lymphoma, the analyst recommends investors remain on the sideline. Shares of the Westminster, Colo.-based biopharmaceutical products company were up 23 cents, or 4.22%, at $5.68. (Nasdaq: ALTH)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.